TIDMNCYT
RNS Number : 0120V
Novacyt S.A.
09 April 2021
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Trading Update
Paris, France and Camberley, UK - 9 April 2021 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in
clinical diagnostics, announces an update on its supply contract
with the UK Department of Health and Social Care (DHSC) and
provides an unaudited trading update for the three months ended 31
March 2021.
DHSC contract
On 29 September 2020, Novacyt announced a second supply contract
with the DHSC for exsig(R) COVID-19 Direct kits and other products.
In the full year trading update announced on 29 January 2021,
Novacyt explained it was in active discussions with the DHSC
regarding an extension of the supply contract. Unfortunately, an
extension has not been agreed, although the Company supplied
PROmate(TM) in Q1 2021 in accordance with DHSC demand. Regrettably,
the parties are now in dispute regarding the contract, which may
have a material impact on Q4 2020 revenues. However, the Company
has taken legal advice and believes it has strong grounds to assert
its contractual rights.
Q1 trading update and 2021 outlook
Novacyt delivered revenue for Q1 2021 of EUR83.0 million
(GBP72.6 million). Approximately 50% of Q1 revenue was driven by
sales to the DHSC, predominately PROmate(TM). The remaining c.50%
of Q1 revenue was driven by continued growth of international sales
and expansion of the Company's private sector testing
operations.
Given the ever-changing nature of the COVID-19 pandemic and
diagnostic testing demands, the Company continues to have limited
visibility over future sales. Whilst the Directors are confident
new contract wins will continue as Novacyt expands international
sales and into private sector testing, they believe revenue and
profit for 2021 may be lower than current market expectations due
to the absence of the DHSC contract extension.
Novacyt expects PROmate(TM) to continue to be rolled out in
hospitals, private sector settings and international markets for
the foreseeable future, although the Company believes that Q1
PROmate(TM) sales may be sufficient to support the NHS current roll
out plans for the remainder of 2021.
The Company is encouraged by demand for its mobile processing
laboratories and SNPsig(R) portfolio, both launched in Q1 2021, for
private sector testing and detection of COVID-19 variants,
respectively. New COVID-19 lateral flow products are also under
development, to expand the Company's ability to meet evolving
COVID-19 testing demands.
The Directors believe the Company remains well-positioned to
capitalise on future growth opportunities as it continues to expand
its product portfolio and service offering.
The information contained within this Announcement is deemed by
the Company to constitute inside information as stipulated under
Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as
amended) as it forms part of the domestic law of the United Kingdom
by virtue of the European Union (Withdrawal) Act 2018 (as amended).
Upon the publication of this Announcement via the Regulatory
Information Service, this inside information is now considered to
be in the public domain.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com; y.petit@allegrafinance.com
FTI Consulting (International)
Victoria Foster Mitchell / Alex Shaw / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
Alex.Shaw@fticonsulting.com/ mary.whittow@fticonsulting.com /
Novacyt.group@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com
About PROmate(TM)
PROmate(TM) is designed to improve the efficiency of COVID-19
testing by repackaging some reagents and reducing the number of
consumables and number of steps required. This decreases operator
complexity and improves cycle times. The PROmate(TM) assay in
combination with the Company's q16 and q32 instrument platforms is
CE-Mark approved and has been independently validated by the UK's
Technology Validation Group (TVG).(1) The TVG accreditation
supports the use of the q16/q32 and PROmate(TM) system in a near
patient setting. PROmate(TM) is the only direct-to-PCR assay with
TVG validation.
[1]
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/957995/TVG_Report-PROmate.pdf
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTBBGDSRBGDGBC
(END) Dow Jones Newswires
April 09, 2021 07:30 ET (11:30 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From Mar 2023 to Mar 2024